Velusetrag

Velusetrag
Clinical data
Routes of
administration
Oral
ATC code None
Legal status
Legal status
  • Investigational drug
Identifiers
Synonyms N-[(3-endo)-8-{(2R)-2-Hydroxy-3-[methyl(methylsulfonyl)amino]propyl}-8-azabicyclo[3.2.1]oct-3-yl]-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamide
CAS Number 866933-46-2
866933-51-9 (hydrochloride)
PubChem (CID) 53297466
IUPHAR/BPS 8425
ChemSpider 28527582
UNII J4VNV64ARB
KEGG D09693
ChEMBL CHEMBL2087337
Chemical and physical data
Formula C25H36N4O5S
Molar mass 504.65 g·mol−1
3D model (Jmol) Interactive image

Velusetrag (INN,[1] USAN; previously known as TD-5108) is an experimental drug candidate for the treatment of gastroparesis, chronic constipation and irritable bowel syndrome.[2] It is a potent, selective, high efficacy 5-HT4 receptor agonist.[3] In clinical trials, velusetrag was efficacious and well tolerated in patients with chronic constipation,[4] and showed accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing.[5]

As of August 31, 2015, clinical trials for chronic constipation and Alzheimer's disease seem to be terminated.[6] One study exploring the efficacy and safety of velusetrag in idiopathic or diabetic gastroparesis is recruiting participants.[7]

See also

References

  1. "WHO Drug Information, Vol. 24, No. 1, 2010. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). World Health Organization. p. 79. Retrieved 26 April 2016.
  2. M. Vazquez-Roque, and M. Camilleri (2011). "Velusetrag". Drugs of the Future. 36 (6): 447–454. doi:10.1358/dof.2011.36.6.1594078 (inactive 2015-02-01).
  3. Smith, JA; Beattie, DT; Marquess, D; Shaw, JP; Vickery, RG; Humphrey, PP (2008). "The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity". Naunyn-Schmiedeberg's archives of pharmacology. 378 (1): 125–37. doi:10.1007/s00210-008-0282-y. PMID 18415081.
  4. Goldberg, M; Li, YP; Johanson, JF; Mangel, AW; Kitt, M; Beattie, DT; Kersey, K; Daniels, O (2010). "Clinical trial: The efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study". Alimentary pharmacology & therapeutics. 32 (9): 1102–12. doi:10.1111/j.1365-2036.2010.04456.x. PMID 21039672.
  5. Manini, ML; Camilleri, M; Goldberg, M; Sweetser, S; McKinzie, S; Burton, D; Wong, S; Kitt, MM; et al. (2010). "Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation". Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 22 (1): 42–9, e7–8. doi:10.1111/j.1365-2982.2009.01378.x. PMC 2905526Freely accessible. PMID 19691492.
  6. "Velusetrag — AdisInsight". Springer International Publishing AG. Retrieved 26 April 2016.
  7. "The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study". ClinicalTrials.gov. Retrieved 26 April 2016.
This article is issued from Wikipedia - version of the 6/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.